Eluvia Is A 'Step Ahead' Of - Not Catching Up To - Rival Peripheral DES, Says BSX
This article was originally published in Clinica
Executive Summary
Peripheral interventions may not be Boston Scientific’s biggest division, but it boasted the highest sales growth among all the other business units in the company’s latest quarterly results. The recent additions to the expanding peripheral interventions portfolio will help maintain this upward trajectory, according to Jane Healy, the recently appointed vice-president of Boston Scientific’s European peripheral interventions unit.
You may also be interested in...
FDA Approves Boston Scientific’s Vici Venous Iliac Stent
The US FDA approval of Boston Scientific's Vici venous stent is based on VIRTUS trial results which met the prespecified performance goal for primary patency after one year.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.